Page 1

ikena ONCOLOGY Ikena Oncology Reports Second Quarter 2021 Financial Results and Provides Update on Key Programs August 12 , 2021 IK - 930 IND on track for submission in 2021 ; multiple upcoming preclinical and translational conference presentations on TEAD inhibition by IK - 930 Progressing IK - 175 clinical trial monotherapy expansion cohort in bladder cancer patients Continued progress across targeted oncology pipeline towards research and clinical milestones BOSTON , Aug. 12 , 2021 ( GLOBE NEWSWIRE ) -- Ikena Oncology , Inc. ( Nasdaq : IKNA , “ Ikena ” ) , a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways , today announced financial results for the quarter that ended June 30 , 2021. The Company also shared updates on several pipeline programs targeting tumor signaling pathways , including Hippo , RAS , and the tumor microenvironment . " In recent months , the Ikena team has continued to generate data on the important targets we are exploring and our development candidates . This work has further elucidated the potential of TEAD inhibition as a monotherapy and in combination with other targeted therapies , and enables us to further refine the clinical development strategy for IK - 930 , our novel TEAD inhibitor , " said Mark Manfredi , PhD , Chief Executive Officer of Ikena Oncology . " We look forward to sharing these and more updates as our data matures and we make strides towards our goal to transform the landscape of cancer treatment to a targeted , patient - focused treatment paradigm . " Ikena is also evaluating our novel AHR antagonist , IK - 175 , in a Phase I clinical trial as a monotherapy and in combination with nivolumab for the treatment of advanced or metastatic solid tumors , including in urothelial carcinoma , a type of bladder cancer where there is a significant unmet need . After completing the monotherapy dose escalation we are progressing the expansion cohort and enrolling additional urothelial carcinoma patients to continue evaluating IK - 175 as a monotherapy and the path towards proof - of - concept in this patient population . " The emerging clinical data observed for IK - 175 monotherapy in urothelial carcinoma and the expansion of the cohort are great steps toward establishing proof of concept . These patients have very limited options for treatment , and we are hopeful that IK - 175 could have significant impact in this setting , " said Sergio Santillana , MD , Chief Medical Officer at Ikena . " The monotherapy cohort expansion is an encouraging development for the Ikena team and ultimately for the patients whose cancer could be treated with this novel therapy . We look forward to generating additional data and providing an update on safety and preliminary anti - tumor activity of IK - 175 at a medical conference in 2022. " Recent Pipeline Progress and Corporate Update • IK - 930 : TEAD Inhibitor in the Hippo Signaling Pathway in IND - enabling Studies • IND - enabling studies continued to progress and the IND submission is on track for the end of 2021 . • Translational and preclinical data will be shared at the EORTC - NCI - AACR 2021 Virtual International Conference on Molecular Targets and Cancer Therapeutics taking place October 7-10 , 2021 . ■ Virtual Poster Presentation of IK - 930 indication selection methodology and data , highlighting a novel method to assess activation across the Hippo pathway and the rationale behind mesothelioma as a cancer type that could benefit from TEAD inhibition as a monotherapy ■ Virtual Poster Presentation of the tumor growth inhibition observed in in vivo preclinical models of lung and colon cancer with IK - 930 combined with inhibition of MEK and EGFR , separately and in triplet • IK - 175 : Clinical Stage AHR Antagonist Partnered with Bristol Myers Squibb ( BMS ) o Ikena is expanding the monotherapy bladder cancer cohort to treat additional patients in the current dose expansion cohort per protocol of the ongoing Phase 1 clinical trial . • Translational and preclinical data will be shared at scientific conferences in the second half of 2021 . • Clinical data presentation planned for a major medical conference in 2022 . • IK - 412 : Novel Enzymatic Therapeutic Degrading Kynurenine Partnered with BMS • Ikena was notified in the second quarter that a key component required in the manufacturing of IK - 412 is also required for the manufacturing of COVID - 19 vaccines and therapies . As a result , the availability of the component for purposes other than vaccine production is extremely limited in the near - term . ■ This situation impacted our manufacturing lead times , delaying the planned IND submission for IK - 412 . ■ Updated guidance on IND submission timing will be provided when material supply of this key component can be reliably projected .